Anti-inflammatory drug evaluation in ApoE-/-mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging

Investigative Radiology

Volumn 47, Issue 9, 2012, Pages 546-552

  Sigovan, Monica ^a,b   Kaye, Elena ^c   Lancelot, Eric ^d   Corot, Claire ^d   Provost, Nicolas ^e   Majd, Zouher ^e   Breisse, Magali ^e   Canet Soulas, Emmanuelle ^f  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Laboratoire Guerbet   (France)

^e GENFIT   (France)

^f UNIVERSITÉ DE LYON   (France)

Author keywords

ApoE; atherosclerosis; irbesartan; USPIO

Indexed keywords

APOLIPOPROTEIN E; IRBESARTAN; IRON OXIDE; LIPID; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CELL CULTURE; CELL LABELING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HISTOLOGY; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84864878405     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182631e68     Document Type: Article

References (22)

1. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
2. Fukuda D, SataM, Ishizaka N, et al. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:90-96.
3. Wassmann S, Czech T, van Eickels M, et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation. 2004;110:3062-3067.
4. Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein EYdeficient mice. J Cardiovasc Pharmacol. 2001;38:395-405.
5. Fukuda D, Enomoto S, Nagai R, et al. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 2009;63:754-761.
6. Gaemperli O, Bengel FM, Kaufmann PA. Cardiac hybrid imaging. Eur Heart J. 2011;32:2100-2108.
7. Patterson AJ, Tang TY, Graves MJ, et al. In vivo carotid plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. NMR Biomed. 2011;24: 89-95.
8. Bessaad A, Sigovan M, Alsaid H, et al. M1-activated macrophages migration, a marker of aortic atheroma progression: a preclinical MRI study in mice. Invest Radiol. 2010;45:262-269.
9. Sigovan M, Bessaad A, Alsaid H, et al. Assessment of age modulated vascular inflammation in ApoEj/j mice by USPIO-enhanced magnetic resonance imaging. Invest Radiol. 2010;45:702-707.
10. Di Marco M, Guilbert I, Port M, et al. Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm. 2007;331:197-203.
11. Sigovan M, Boussel L, Sulaiman A, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology. 2009;252:401-409.
12. Wilhelm C, Gazeau F. Universal cell labelling with anionic magnetic nanoparticles. Biomaterials. 2008;29:3161-3174.
13. Sabbah M, Alsaid H, Fakri-Bouchet L, et al. Real-time gating system for mouse cardiovascular MR imaging. Magn Reson Med. 2007;57:29-39.
14. Mansard CD, Canet Soulas EP, Anwander A, et al. Quantification of multicontrast vascular MR images with NLSnake, an active contour model: in vitro validation and in vivo evaluation. Magn Reson Med. 2004;51:370-379.
15. Tang TY, Muller KH, Graves MJ, et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol. 2009;29:1001-1008.
16. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol. 2010;88:33-39.
17. Levy M, Wilhelm C, Luciani N, et al. Nanomagnetism reveals the intracellular clustering of iron oxide nanoparticles in the organism. Nanoscale. 2011;3: 4402-4410.
18. Levy M, Luciani N, Alloyeau D, et al. Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials. 2011;32:3988-3999.
19. Nussberger J, Aubert JF, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51:1306-1311.
20. Fukuda D, Enomoto S, Hirata Y, et al. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. Biomed Pharmacother. 2010;64:712-717.
21. Osada-Oka M, Kita H, Yagi S, et al. Angiotensin AT1 receptor blockers suppress oxidized low-density lipoprotein-derived formation of foam cells. Eur J Pharmacol. 2012;679:9-15.
22. Zhou Y, Chen R, Catanzaro SE, et al. Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-EYdeficient mice. Am J Hypertens. 2005;18:486-492.